Marshall Wace, LLP Sellas Life Sciences Group, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 11,482 shares of SLS stock, worth $20,667. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,482Holding current value
$20,667% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding SLS
# of Institutions
53Shares Held
14.9MCall Options Held
538KPut Options Held
26.3K-
Anson Funds Management LP Dallas, TX7.58MShares$13.6 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.84MShares$5.11 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.48 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA689KShares$1.24 Million0.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$774,6620.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $37M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...